Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

Maximizing Impact and Utility of Prognostic Gene Testing in Melanoma and Squamous Cell Carcinoma : Episode 5

Opinion

Video

April 4, 2025

De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC

Author(s):

An expert discusses their impressions of the case, classifying the patient’s risk based on the clinical presentation of the lesion, and outlines treatment recommendations without knowing the 40-gene expression profile (GEP) information, including whether adjuvant therapy (ART) would be recommended. The expert also shares how to discuss 40-GEP testing with patients and reassure them that accurate risk levels are crucial for receiving optimal treatment.

EP: 1.Limitations and Challenges in Skin Cancer Staging Systems

EP: 2.Utility of Molecular Testing in Skin Cancer Risk Assessment

EP: 3.Gene Expression Profiling and Other Molecular Tests Utilized for Melanoma and Squamous Cell Carcinoma

EP: 4.Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma

Now Viewing

EP: 5.De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC

EP: 6.Key Takeaways on GEP Testing in Melanoma and SCC

Video content above is prompted by the following:

What are your impressions of this case? Based on the clinical presentation of the lesion, how would you classify the patient’s risk?
Without knowing the 40-GEP information, what would your treatment recommendation be? Would you recommend ART for this patient?
How do you discuss 40-GEP testing with your patients? How can you best reassure patients that an accurate risk level is critical to receiving optimal treatment?

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!